"A Pilot Window-3 Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma"

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 18, 2022

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions

LymphomaMantle Cell Lymphoma

Interventions

DRUG

Acalabrutinib

Given by PO

DRUG

Rituximab

Given by IV (vein)

OTHER

Brexucabtagene Autoleucel

Given by IV (vein)

DRUG

Cyclophosphamide

Given by IV (vein)

DRUG

Fludarabine Phosphate

Given by IV (vein)

Trial Locations (1)

M D Anderson Cancer Center, Houston